Reduced plasma calcitonin gene-related peptide level identified in cluster headache: A prospective and controlled study.

IF 5 2区医学 Q1 CLINICAL NEUROLOGY

Cephalalgia Pub Date : 2024-03-01 DOI:10.1177/03331024231223970

Anja Sofie Petersen, Nunu Lund, Karl Meßlinger, Sarah Louise Christensen, Mads Barloese, Niklas Rye Jørgensen, Lisette Kogelman, Rigmor Højland Jensen

{"title":"Reduced plasma calcitonin gene-related peptide level identified in cluster headache: A prospective and controlled study.","authors":"Anja Sofie Petersen, Nunu Lund, Karl Meßlinger, Sarah Louise Christensen, Mads Barloese, Niklas Rye Jørgensen, Lisette Kogelman, Rigmor Højland Jensen","doi":"10.1177/03331024231223970","DOIUrl":null,"url":null,"abstract":"Background: The role of calcitonin gene-related peptide (CGRP) in the cyclic pattern of cluster headache is unclear. To acquire biological insight and to comprehend why only episodic cluster headache responds to CGRP monoclonal antibodies, we examined whether plasma CGRP changes between disease states (i.e. bout, remission and chronic) and controls.Methods: The present study is a prospective case-control study. Participants with episodic cluster headache were sampled twice (bout and remission). Participants with chronic cluster headache and controls were sampled once. CGRP concentrations were measured in plasma with a validated radioimmunoassay.Results: Plasma was collected from 201 participants diagnosed with cluster headache according to the International Classification of Headache Disorders, 3rd edition, and from 100 age- and sex-matched controls. Overall, plasma CGRP levels were significantly lower in participants with cluster headache compared to controls (p < 0.05). In episodic cluster headache, CGRP levels were higher in bout than in remission (mean difference: 17.1 pmol/L, 95% confidence interval = 9.8-24.3, p < 0.0001). CGRP levels in bout were not different from chronic cluster headache (p = 0.266).Conclusions: Plasma CGRP is unsuitable as a diagnostic biomarker of cluster headache or its disease states. The identified reduced CGRP levels suggest that CGRPs role in cluster headache is highly complex and future investigations are needed into the modulation of CGRP and its receptors.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 3","pages":"3331024231223970"},"PeriodicalIF":5.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cephalalgia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03331024231223970","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The role of calcitonin gene-related peptide (CGRP) in the cyclic pattern of cluster headache is unclear. To acquire biological insight and to comprehend why only episodic cluster headache responds to CGRP monoclonal antibodies, we examined whether plasma CGRP changes between disease states (i.e. bout, remission and chronic) and controls.

Methods: The present study is a prospective case-control study. Participants with episodic cluster headache were sampled twice (bout and remission). Participants with chronic cluster headache and controls were sampled once. CGRP concentrations were measured in plasma with a validated radioimmunoassay.

Results: Plasma was collected from 201 participants diagnosed with cluster headache according to the International Classification of Headache Disorders, 3rd edition, and from 100 age- and sex-matched controls. Overall, plasma CGRP levels were significantly lower in participants with cluster headache compared to controls (p < 0.05). In episodic cluster headache, CGRP levels were higher in bout than in remission (mean difference: 17.1 pmol/L, 95% confidence interval = 9.8-24.3, p < 0.0001). CGRP levels in bout were not different from chronic cluster headache (p = 0.266).

Conclusions: Plasma CGRP is unsuitable as a diagnostic biomarker of cluster headache or its disease states. The identified reduced CGRP levels suggest that CGRPs role in cluster headache is highly complex and future investigations are needed into the modulation of CGRP and its receptors.

查看原文本刊更多论文

集束性头痛患者血浆降钙素基因相关肽水平降低：前瞻性对照研究

背景：降钙素基因相关肽（CGRP）在丛集性头痛周期性模式中的作用尚不清楚。为了获得生物学洞察力并理解为什么只有发作性丛集性头痛对CGRP单克隆抗体有反应，我们研究了血浆CGRP在疾病状态（即发作期、缓解期和慢性期）和对照组之间是否有变化：本研究是一项前瞻性病例对照研究。方法：本研究是一项前瞻性病例对照研究，对发作性丛集性头痛患者进行两次采样（发作期和缓解期）。对慢性丛集性头痛患者和对照组取样一次。采用有效的放射免疫测定法测量血浆中 CGRP 的浓度：从 201 名根据《国际头痛疾病分类》第三版诊断为丛集性头痛的患者和 100 名年龄和性别匹配的对照组患者中采集了血浆。总体而言，与对照组相比，丛集性头痛患者的血浆 CGRP 水平明显较低（P P = 0.266）：结论：血浆 CGRP 不适合作为丛集性头痛或其疾病状态的诊断生物标志物。已确定的 CGRP 水平降低表明，CGRP 在丛集性头痛中的作用非常复杂，今后需要对 CGRP 及其受体的调节进行研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cephalalgia 医学-临床神经学

CiteScore

10.10

自引率

6.10%

发文量

108

审稿时长

4-8 weeks

期刊介绍： Cephalalgia contains original peer reviewed papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications. Published monthly on behalf of the International Headache Society, Cephalalgia''s rapid review averages 5 ½ weeks from author submission to first decision.